E Fund Management Co. Ltd. Makes New $369,000 Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

E Fund Management Co. Ltd. bought a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,385 shares of the company’s stock, valued at approximately $369,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in shares of IDEAYA Biosciences by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,474 shares of the company’s stock valued at $40,000 after buying an additional 723 shares during the period. AJOVista LLC purchased a new stake in shares of IDEAYA Biosciences during the 4th quarter valued at $99,000. Exchange Traded Concepts LLC grew its stake in shares of IDEAYA Biosciences by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company’s stock valued at $171,000 after buying an additional 1,219 shares during the period. Callan Capital LLC purchased a new stake in shares of IDEAYA Biosciences during the 4th quarter valued at $239,000. Finally, Amalgamated Bank grew its stake in shares of IDEAYA Biosciences by 6.4% during the 3rd quarter. Amalgamated Bank now owns 7,205 shares of the company’s stock valued at $194,000 after buying an additional 433 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on IDYA shares. Royal Bank of Canada boosted their price objective on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, February 21st. Leerink Partnrs reaffirmed an “outperform” rating on shares of IDEAYA Biosciences in a research report on Friday, February 23rd. JPMorgan Chase & Co. upped their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Capital One Financial reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research report on Thursday, February 22nd. Finally, BTIG Research initiated coverage on shares of IDEAYA Biosciences in a research report on Friday, March 8th. They set a “buy” rating and a $55.00 price target for the company. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $47.50.

Insider Activity

In other news, CEO Yujiro S. Hata sold 23,557 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.54, for a total value of $1,072,785.78. Following the sale, the chief executive officer now owns 677,887 shares in the company, valued at approximately $30,870,973.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Yujiro S. Hata sold 23,557 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.54, for a total value of $1,072,785.78. Following the sale, the chief executive officer now owns 677,887 shares in the company, valued at approximately $30,870,973.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Briseno Andres Ruiz sold 2,000 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the sale, the insider now owns 24,531 shares in the company, valued at approximately $1,128,916.62. The disclosure for this sale can be found here. Company insiders own 3.50% of the company’s stock.

IDEAYA Biosciences Trading Down 1.9 %

IDYA stock traded down $0.77 during trading on Thursday, reaching $40.64. The stock had a trading volume of 406,385 shares, compared to its average volume of 829,828. IDEAYA Biosciences, Inc. has a 1-year low of $20.68 and a 1-year high of $47.74. The company has a market capitalization of $3.04 billion, a P/E ratio of -20.22 and a beta of 0.83. The firm has a fifty day moving average price of $42.57 and a 200 day moving average price of $38.40.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. During the same quarter last year, the business posted ($0.49) earnings per share. The business’s revenue was down 100.0% compared to the same quarter last year. Sell-side analysts predict that IDEAYA Biosciences, Inc. will post -2.26 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.